Prior Expectations
Hims & Hers Health has faced a tumultuous year, with its share price more than halving over the past 12 months. Despite a recent 30-day return of 35.49% and a year-to-date return of 52.89%, the company had been grappling with regulatory setbacks and a lawsuit from Novo Nordisk concerning compounded GLP-1 drugs. The last recorded share price was $15.74, significantly below its estimated fair value of $86.09.
Decisive Moment
A pivotal change occurred when Hims & Hers Health announced a partnership with Novo Nordisk, which plans to sell its weight-loss drugs on Hims’ platform. This development resolved a legal dispute that had escalated between the two companies, marking a significant turnaround for Hims.
Following the announcement of the partnership, Hims shares surged by 39% in after-hours trading, reflecting a strong investor response to the news. This surge contrasts sharply with the company’s previous struggles and highlights a renewed confidence in its business model.
Expert Perspectives
According to a spokesperson from Novo Nordisk, the company is “always in conversation with companies that can help improve patient access to FDA-approved medicines.” This sentiment underscores the strategic importance of the partnership for both companies, as Hims & Hers Health positions itself as a key player in the healthcare infrastructure in the United States.
As one analyst noted, “Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock; it is quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States.” This perspective suggests that the partnership could pave the way for further growth and innovation within the company.
Looking Ahead
While the partnership with Novo Nordisk marks a significant step forward for Hims & Hers Health, uncertainties remain regarding the impact of regulatory changes on its business model. Details remain unconfirmed, leaving investors and analysts to watch closely as the situation develops.
